Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CTBP2 | P56545 | 2/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153981 | 1.00 | BCAT2 (0.51) | BCAT2AKR1B1TDP1LMNAGAA | |
| Water SCHEMBL871348 | 0.98 | BCAT2 (0.50) | BCAT2AKR1B1TDP1LMNAGAA | |
| SCHEMBL18716529 | 0.81 | BCAT2 (0.58) | BCAT2AKR1B1TDP1LMNAL3MBTL1 | |
| SCHEMBL13770580 | 0.80 | GAA (0.43) | BCAT2LMNAGAAL3MBTL1CTBP2 | |
| SCHEMBL103625 | 0.79 | GAA (0.46) | LMNAGAAL3MBTL1CTBP2MAPT | |
| SCHEMBL103624 | 0.79 | GAA (0.46) | LMNAGAAL3MBTL1CTBP2MAPT | |
| SCHEMBL19153141 | 0.79 | TDP1 (0.46) | BCAT2AKR1B1TDP1LMNAGAA | |
| SCHEMBL27598452 | 0.78 | BCAT2 (0.54) | BCAT2AKR1B1TDP1LMNAABCB11 | |
| SCHEMBL7459186 | 0.77 | GAA (0.47) | LMNAGAAL3MBTL1CYP2C19CYP2C9 | |
| 2-Carboxybenzeneacetic Acid SCHEMBL27477 | 0.77 | AKR1B1 (0.61) | BCAT2AKR1B1TDP1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376074-B1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | DRITTE PATENTPORTFOLIO BETEILI (DE) | 2019-03-13 | — | — | EP | disclosed |
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | DRITTE PATENTPORTFOLIO BETEILIGUNGSGESELLSCHAFT MBH & CO. KG (DE) | 2012-03-29 | — | — | US | disclosed |
| CN-102378628-A | Method for improved bioactivation of medications | UNIV KIEL CHRISTIAN ALBRECHTS | 2012-03-14 | — | — | CN | disclosed |
| EP-2376074-A1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | Dritte Patentportfolio Beteiligungsgesellschaft mbH & Co. KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010078867-A1 | METHOD FOR IMPROVED BIOACTIVATION OF MEDICATIONS | CHRISTIAN-ALBRECHTS-UNIVERSITÄT ZU KIEL (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077876-A1 | Method For Improved Bioactivation Of Pharmaceuticals | CYP2B6, CYP1A2, CYP2D6 | BCAT2 2525/4885AKR1B1 63/4885TDP1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.